Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia
Source: Acta Psychiatrica Scandinavica, Volume 113, Supplement 430, May 2006 , pp. 12-21(10)
Abstract:Williams R, Kopala L, Malla A, Smith G, Love L, Balshaw R. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatr Scand 2006: 113 (Suppl. 430): 12–21. © 2006 Blackwell Munksgaard. Objective: To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment. Method: A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years. Results: Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized. Conclusion: There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period.
Document Type: Research article
Publication date: 2006-05-01